Table 1 Baseline characteristics of patients with gastric cancer undergoing gastrectomy in the training and validation cohorts (n = 356)
From: A novel immunohistochemical score predicts the postoperative prognosis of gastric cancer patients
Training cohort (n = 245) | Validation cohort (n = 111) | p value | |
|---|---|---|---|
Gender (%) | 0.929 | ||
Male | 204 (83.3) | 92 (82.9) | |
Female | 41 (16.7) | 19 (17.1) | |
Age (%) | 0.566 | ||
< 60 years | 137 (55.9) | 58 (52.3) | |
≥ 60 years | 108 (44.1) | 53 (47.7) | |
ASA (%) | 0.307 | ||
I | 217 (88.6) | 94 (84.7) | |
II | 28 (11.4) | 17 (15.3) | |
ECOG PS (%) | 0.888 | ||
0 | 193 (78.8) | 89 (80.2) | |
1 | 52 (21.2) | 22 (19.8) | |
Depth of tumor invasion (%) | 0.721 | ||
T1 | 49 (20.0) | 20 (18.0) | |
T2 | 25 (10.2) | 11 (9.9) | |
T3 | 126 (51.4) | 59 (53.2) | |
T4 | 45 (18.4) | 21 (18.9) | |
N status (%) | 0.132 | ||
N0 | 56 (22.9) | 28 (25.2) | |
N1 | 63 (25.7) | 23 (20.7) | |
N2 | 62 (25.3) | 25 (22.5) | |
N3 | 64 (26.1) | 35 (31.5) | |
TNM stage (%) | 0.081 | ||
I stage | 61 (24.9) | 40 (36.0) | |
II stage | 38 (15.5) | 34 (30.6) | |
III stage | 81 (33.1) | 20 (18.0) | |
IV stage | 65 (26.5) | 17 (15.3) | |
Tumor size (%) | 1.000 | ||
< 5 cm | 110 (44.9) | 50 (45.0) | |
≥ 5 cm | 135 (55.1) | 61 (55.0) | |
Differentiation (%) | 0.547 | ||
High or moderate | 86 (35.1) | 35 (31.5) | |
Poor or no | 159 (64.9) | 76 (68.5) | |
Vascular invasion (%) | 0.809 | ||
No | 82 (33.5) | 39 (35.1) | |
Yes | 163 (66.5) | 72 (64.9) | |
P53 (%) | 0.354 | ||
No | 138 (56.3) | 69 (62.2) | |
Yes | 107 (43.7) | 42 (37.8) | |
Ki-67 (%) | 0.304 | ||
< 50% | 129 (52.7) | 65 (58.6) | |
≥ 50% | 116 (47.3) | 46 (41.4) | |
MSI status (%) | 0.777 | ||
MSS/MSI-low | 195 (79.6) | 90 (81.1) | |
MSI-high | 50 (20.4) | 21 (18.9) | |
Follow-up period | |||
Month (95%CI) | 49.0 (41.4–55.6) | 56.0 (47.6–68.8) | 0.130 |
Recurrence model | 0.513 | ||
Local recurrence | 44 (18.0) | 21 (18.9) | |
Lymph node metastasis | 33 (13.5) | 17 (15.3) | |
Intra-abdominal metastasis | 70 (28.6) | 34 (30.6) | |
Other organ metastases | 39 (15.9) | 14 (12.6) | |